3
Press Release STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market
One document
more
Stories about Krankheit
Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
Aachen, Germany & Toronto, Canada, (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, ...
moreNew Knowledge Portal Adiposetissue.org Enhances Obesity and Metabolism Research with Centralized Data
moreX4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.
London (ots/PRNewswire) - Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare ...
moreAncient Viral DNA Shapes Early Embryo Development
Over half of our genomes consists of thousands of remnants of ancient viral DNA, known as transposable elements, which are widespread across the tree of life. Once dismissed as the "dark side" of the genome, researchers at Helmholtz Munich and Ludwig-Maximilians-Universität (LMU) have now revealed their crucial role in early embryo development. Unanswered Questions About the Role of Ancient Viral DNA Transposable ...
moreSCP-Nano: A New Technology to Visualize Nanocarriers in Cells and Tissues
more
Bosch Healthcare Solutions GmbH
Vivalytic Bacterial Meningitis by Bosch: PCR rapid test for medical emergencies
moreBIAL Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 - a Novel Therapy for GBA1 Parkinson's Disease
Porto, Portugal (ots/PRNewswire) - BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced that the first patient has completed the full dose regimen in the ACTIVATE Phase 2 study. BIA 28-6156 is a first-in-class, small molecule for once-daily oral ...
moreNorgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
London (ots/PRNewswire) - Back to media releases Next media release Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in ...
moreRHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers
moreAccord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®
London (ots/PRNewswire) - - Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases. - The EC approval follows a positive opinion issued on 19 October ...
moreMaria-Elena Torres-Padilla Honored With the Leibniz Prize 2025
more
Technische Universität München
Complex pancreatic tumor organoids as foundation for new treatment strategies
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Foundation for new cancer treatment strategies Organoids represent the complex cell landscape of pancreatic cancer - Tumors are composed of cancer cells with a variety of different characteristics. - This contributes significantly to the complexity of pancreatic cancer and makes the disease difficult to treat. - For the ...
moreObrist Group Introduces Alternatives to PFAS and F-Gases
Obrist Group Introduces Alternatives to PFAS and F-Gases Natural Refrigerants Replacing Harmful Forever Chemicals in Cars Lindau/Germany, Lustenau/Austria – December 10 2024 – Per- and polyfluoroalkyl substances (PFAS) are recognized as highly hazardous, and the European Union is preparing to ban these toxic chemicals. The PFAS group also includes F-gases, such as hydrofluorocarbons, which are widely used in cooling ...
moreGEA launches Body Condition Scoring for cows
One documentmoreEuropean Alliance Against Depression
First European Patient Congress Depression for those affected by depression and their close relations takes place online on December 7, 2024 / Free online-event offers information and experience-sharing
Frankfurt am Main (ots) - The European Patient Congress Depression, hosted by the European Alliance Against Depression (EAAD), will take place on December 7, 2024. This free online-event is designed to support individuals affected by depression and their relatives, providing a platform for expert guidance, patient ...
moreInceptor Regulates Insulin Homeostasis: A New Approach for Diabetes Therapies
moreLast Call for canSERV Third Open Call Funding
One documentmore
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...
moreFirst participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...
moreEvent Announcement: VIROFIGHT Hybrid Symposium
One documentmorePress Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar
EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...
moreExtreme Rainfall Poses Health Risks
Extreme Rainfall Poses Health Risks An international study led by Helmholtz Munich investigates the health consequences of heavy rainfall events. Researchers analyzed the relationship between precipitation patterns and mortality rates at 645 locations across 34 countries from 1980 to 2020. The key finding: Extremely heavy rainfall, which occurs approximately every five years, significantly increases the risk of death, ...
moreRHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU
more
Launch of canSERV Call for Service Provision – "Training the Next Generation of Cancer Researchers"
One documentmore- 2
Fundació Puigvert validates a new tool capable of selecting the most suitable antibiotic for uncomplicated urinary tract infections within 45 minutes.
One documentmore INSIGHTEC; Charles River Laboratories International, Inc.
Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
Wilmington, Mass., Miami and Haifa, Israel (ots/PRNewswire) - Collaboration stands to advance novel therapeutic applications across multiple neurologic conditions Charles River Laboratories International, Inc. (NYSE: CRL) and Insightec, a global healthcare company dedicated to using focused ultrasound to transform ...
more- 2
Record financing rounds at the Munich biotech hub
One documentmore Bosch Healthcare Solutions GmbH
Near-patient PCR rapid test for whooping cough for Vivalytic by Bosch now available / World's first fully automated PCR test for detection of B. pertussis, B. parapertussis, B. holmesii
morecanSERV relaunches Open Call for Service Provision
One documentmore
12345678910Next